SS-31 (Elamipretide) displaces α-synuclein from membranes, inhibits aggregation, and restores mitochondrial function in neuroblastoma cells.
Background
Parkinson's disease (PD) and related synucleinopathies are characterized by the abnormal aggregation of α-synuclein (αSyn) into insoluble Lewy bodies, a process closely linked to neuronal dysfunction and death. This aggregation also impairs mitochondrial function, a critical factor in neurodegeneration. Current therapeutic strategies often fall short in directly targeting αSyn aggregation or restoring mitochondrial health. SS-31 (Elamipretide), a known mitochondrial inner membrane-targeting tetrapeptide, offers a potential avenue to address this gap by modulating αSyn interaction with membranes and mitigating mitochondrial impairment.
Study Design
Researchers investigated SS-31's effects on α-synuclein using various in-vitro models. They employed fluorescence correlation spectroscopy and fluorescence anisotropy to assess SS-31's ability to displace wild-type and N-terminal acetylated α-synuclein from negatively charged small unilamellar vesicles. Thioflavin-T assay and transmission electron microscopy were used to evaluate SS-31's impact on membrane-induced α-synuclein aggregation and fibril morphology. To assess cellular effects, MTT assay and Seahorse Mito Stress Test were performed on α-synuclein oligomer-treated neuroblastoma cells. Finally, confocal imaging examined SS-31's influence on cellular uptake of α-synuclein oligomers.
Results
SS-31 demonstrated a clear ability to modulate α-synuclein behavior. Both fluorescence correlation spectroscopy and fluorescence anisotropy showed that SS-31 displaces wild-type and N-terminal acetylated α-synuclein from negatively charged small unilamellar vesicles in a dose-dependent manner. Furthermore, Thioflavin-T assay and transmission electron microscopy revealed that SS-31 inhibits membrane-induced α-synuclein aggregation and alters the morphology of α-synuclein fibrils. In cellular models, MTT assay indicated that SS-31 enhances cell viability in α-synuclein oligomer-treated neuroblastoma cells. The Seahorse Mito Stress Test confirmed that SS-31 restores impaired mitochondrial function in these cells. Finally, confocal imaging provided evidence that SS-31 hinders cellular uptake of α-synuclein oligomers, potentially by modifying cell membrane electrostatics. This multifaceted action suggests a comprehensive protective mechanism.
SS-31 significantly enhanced cell viability and restored impaired mitochondrial function in
α-synucleinoligomer-treated neuroblastoma cells, directly addressing a key pathological feature of synucleinopathies.
Key Findings
- SS-31 dose-dependently displaces α-synuclein from negatively charged lipid membranes.
- SS-31 inhibits membrane-induced α-synuclein aggregation and alters fibril morphology.
- SS-31 enhances cell viability in α-synuclein oligomer-treated neuroblastoma cells.
- SS-31 restores impaired mitochondrial function in α-synuclein oligomer-treated neuroblastoma cells.
- SS-31 hinders cellular uptake of α-synuclein oligomers, possibly via membrane electrostatics.
Why It Matters
SS-31 shows promise as a therapeutic strategy for Parkinson's disease by directly targeting α-synuclein pathology and mitochondrial health. For peptide users and biohackers, these findings highlight SS-31's potential beyond its known mitochondrial benefits, suggesting a role in neuroprotection against protein aggregation. The ability to modulate α-synuclein interaction with membranes and restore mitochondrial function could lead to novel interventions for neurodegenerative diseases. While currently in-vitro, this research supports further development of SS-31 or similar mitochondrial-targeting peptides, potentially impacting future protocols for managing or preventing neurodegenerative conditions where α-synuclein aggregation and mitochondrial dysfunction are central.
ss-31
elamipretide
parkinsons-disease
alpha-synuclein
mitochondrial-function
neuroprotection